Abstract | BACKGROUND AND OBJECTIVE: METHODS: Twenty Chinese patients with spontaneous subarachnoid haemorrhage at least 9 months after the initial ictus, and with persistent cognitive impairment, were recruited. The primary outcome measure was Cognitive Subscale of Alzheimer Disease Assessment Scale (ADAS-cog) for global function; the secondary outcome measures were the Frontal Assessment Battery (FAB) for frontal lobe function and the Rivermead Behavioural Memory Test (RBMT) for prospective memory. Baseline cholinergic dysfunction (with pupillometry) was assessed for relationship with treatment efficacy. RESULTS: Sixteen of 20 (80%) patients completed the 12-week course of rivastigmine 1.5 mg twice daily. In comparison with the baseline assessment, ADAS-cog showed significant improvement after treatment (mean difference 6.5, 95% CI 3.5-9.5, P < 0.001); FAB and RBMT also showed significant improvement. Baseline cholinergic dysfunction (with pupillometry) was not correlated with improvement in ADAS-cog, FAB or RBMT. CONCLUSION:
|
Authors | G K-C Wong, R Wong, V Mok, A Wong, D Fan, G Leung, A Chan, W S Poon |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 34
Issue 6
Pg. 657-63
(Dec 2009)
ISSN: 1365-2710 [Electronic] England |
PMID | 20175798
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholinesterase Inhibitors
- Phenylcarbamates
- Rivastigmine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cholinesterase Inhibitors
(therapeutic use)
- Cognition Disorders
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Neuropsychological Tests
- Phenylcarbamates
(therapeutic use)
- Pilot Projects
- Rivastigmine
- Subarachnoid Hemorrhage
(complications)
|